Research Article
Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis
Table 1
Patients’ characteristics.
| Study population | Description |
| Number of patients ( = 1090) | AED/amitriptyline: 342 (31%; 249 females) | Gender distribution | Mean age 53 (±10) years | Age distribution | Patients 60 years and above (29%; = 100) | Range | 21–73 years |
| EDSS score | MS Rehabilitation Centre population: mean 4.8 (±1.8, = 585) AED/amitriptyline: mean 4.8 (±1.7; = 196) |
| Polypharmacy | AED/amitriptyline: 5.4 (range 1–19) different prescription drugs 203 (59%) used 5 or more drugs 24 (7%) used 10 drugs or more |
| Comorbid disorders, epilepsy | MS Rehabilitation Centre population: = 20 (1.8%), diagnosis of epilepsy | Mood disorder | AED/amitriptyline: = 71 (21% used either -blocker, SNRI or SSRI) |
| Use of disease-modifying drugs | AED/amitriptyline: = 130 (38%) Natalizumab: = 40 (12%) Glatiramer acetate: = 37 (11%) Interferon-beta: = 36 (11%) Mitoxantrone: = 7 (2%) Fingolimod: = 6 (2%) Ocrelizumab: = 1 (0.3%) |
|
|